In order to reduce the side effects of traditional chemotherapy in the treatment of colorectal cancer (CRC), Researchers at the University of Salamanca have developed a new drug delivery system based on exosomes that can host two drugs that act synergistically: farnesol (that stops the cell cycle) and paclitaxel (prevents microtubule system depolymerization). Firstly, exosomes were isolated from different cell cultures (from colorectal cancer and from fibroblast as example of normal cell line) by different methods and characterized by western blot, TEM and DLS, and results showed that they express classical protein markers such as CD9 and HSP-70 and they showed spherical morphology with sizes from 93 nm to 129 nm depending on the source. These exosomes were loaded with both drugs and its effect was studied in vitro. The efficacy was studied by comparing the viability of cell cultures with a colorectal cancer cell line (HCT-116) and a normal cell line (fibroblast HS-5). Results showed that exosomes present a specific effect with more reduction in cell viability in tumour cultures than healthy ones. In summary, exosomes are presented in this work as a promising strategy for colorectal cancer treatment.
A synergistic approach therapy for colorectal cancer based on exosomes and exploitation of metabolic pathways
de Dios-Pérez I, González-Garcinuño A, Muñoz-Barroso I, Martín del Valle EM. (2023) A Synergistic Approach Therapy for Colorectal Cancer Based on Exosomes and Exploitation of Metabolic Pathways. JPharmSci [Epub ahead of print]. [article]